Your browser doesn't support javascript.
loading
Classification of gastrocnemius muscle hypertrophy for personalized botulinum toxin type A treatment.
Liu, Dandan; Xu, Xiangwen; Wu, Mengfan; Luo, Lin; Feng, Jun; Ou, Yanting; Panayi, Adriana C; Long, Yun; Cui, Yongyan.
Afiliação
  • Liu D; Department of Plastic and Reconstructive Surgery, Peking university Shenzhen hospital, Shenzhen, China.
  • Xu X; Department of Plastic and Reconstructive Surgery, Peking university Shenzhen hospital, Shenzhen, China.
  • Wu M; Department of Plastic and Reconstructive Surgery, Peking university Shenzhen hospital, Shenzhen, China.
  • Luo L; Department of Plastic and Reconstructive Surgery, Peking university Shenzhen hospital, Shenzhen, China.
  • Feng J; Department of Plastic and Reconstructive Surgery, Peking university Shenzhen hospital, Shenzhen, China.
  • Ou Y; Department of Plastic and Reconstructive Surgery, Peking university Shenzhen hospital, Shenzhen, China.
  • Panayi AC; Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Long Y; Department of Plastic and Reconstructive Surgery, Peking university Shenzhen hospital, Shenzhen, China.
  • Cui Y; Department of Plastic and Reconstructive Surgery, Peking university Shenzhen hospital, Shenzhen, China.
J Cosmet Dermatol ; 23(1): 90-98, 2024 Jan.
Article em En | MEDLINE | ID: mdl-37529982
ABSTRACT

BACKGROUND:

Owing to its safety and convenience, botulinum toxin type A (BoNtA) has become a first-choice treatment for contouring calf muscle asymmetries or deformities. Different injection methods and dosages have been discussed in the literature, but a standardized BoNtA treatment remains unclear.

AIMS:

This study aimed to classify gastrocnemius muscle hypertrophy (GMH) through multiple measurements to provide a personalized BoNtA treatment protocol.

METHODS:

The measurements combining of gastrocnemius muscle (GM) contour, max leg circumference and GM thickness was applied to classify different type of GMH in a normal population. Based on these findings, a personalized BoNtA treatment protocol was determined and evaluated regarding max leg circumference, GM thickness, the position of max leg circumference, patient and doctor satisfaction rate, and complications.

RESULTS:

A total of 100 GMH were classified into two bulging types (bilateral-bulging type and unilateral-bulging type) and two categories (moderate GMH and severe GMH). 40 cases were treated with personalized BoNtA injection methods ("Even" or "Intense"method) and dosages (300 or 400 units). Follow-up examinations at 1, 3, and 6 months after treatment. Max leg circumference and GM thickness decreased significantly and the position of max leg circumference rose prominently during treatment (2.56 ± 1.93; p < 0.05). The overall patient satisfaction rate was 70%-100%. No serious complications occurred.

CONCLUSIONS:

We identify four groups of GMH through several measurements and outline a personalized BoNtA treatment for each type. This recommended protocol may improve the therapeutic outcomes and patient satisfaction after treatment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Toxinas Botulínicas Tipo A / Fármacos Neuromusculares Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: J Cosmet Dermatol Assunto da revista: DERMATOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Toxinas Botulínicas Tipo A / Fármacos Neuromusculares Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: J Cosmet Dermatol Assunto da revista: DERMATOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China